Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $155M | $175M | $202M | $231M | $207M | $274M | $330M | $399M | $465M | $535M |
| Revenue growth | — | 12.6% | 15.4% | 14.5% | -10.5% | 32.8% | 20.4% | 20.8% | 16.5% | 14.9% |
| Gross profit | $111M | $126M | $147M | $170M | $149M | $206M | $246M | $300M | $348M | $401M |
| Gross margin | 71.6% | 72.2% | 73.0% | 73.8% | 72.3% | 75.0% | 74.4% | 75.2% | 74.7% | 75.0% |
| Operating income | -$31.1M | -$25.0M | -$17.1M | -$33.1M | -$44.2M | $55.2M | -$42.7M | -$26.7M | -$40.0M | -$9.45M |
| Operating margin | -20.1% | -14.3% | -8.5% | -14.4% | -21.4% | 20.1% | -12.9% | -6.7% | -8.6% | -1.8% |
| Net income | -$33.3M | -$26.9M | -$21.1M | -$35.2M | -$48.2M | $50.2M | -$46.5M | -$30.4M | -$44.7M | -$11.4M |
| Net margin | -21.5% | -15.4% | -10.5% | -15.2% | -23.3% | 18.3% | -14.1% | -7.6% | -9.6% | -2.1% |
| EPS (diluted) | -$1.05 | -$0.83 | -$0.62 | -$0.94 | -$1.14 | $1.09 | -$1.02 | -$0.66 | -$0.95 | -$0.24 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.1M | -$8.94M | -$4.17M | -$15.8M | -$19.9M | -$13.8M | -$22.1M | $4.48M | $12.2M | $57.3M |
| Capital expenditures | $7.69M | $6.38M | $6.21M | $12.2M | $5.26M | $9.75M | $16.9M | $12.0M | $11.5M | $9.05M |
| Free cash flow | -$22.8M | -$15.3M | -$10.4M | -$28.0M | -$25.1M | -$23.5M | -$39.0M | -$7.51M | $745K | $48.3M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $24.2M | $21.8M | $32.2M | $28.5M | $41.9M | $43.7M | $58.1M | $84.3M | $123M | $167M |
| Total assets | $276M | $268M | $357M | $558M | $715M | $615M | $585M | $614M | $609M | $654M |
| Total liabilities | $108M | $107M | $107M | $311M | $302M | $132M | $129M | $148M | $148M | $162M |
| Long-term debt | $23.9M | $24.1M | $35.6M | $59.6M | $53.4M | $59.7M | $56.8M | $60.6M | $61.0M | $61.9M |
| Shareholders' equity | $168M | $161M | $249M | $247M | $412M | $484M | $457M | $466M | $461M | $492M |
| Retained earnings | -$199M | -$226M | -$247M | -$282M | -$330M | -$280M | -$327M | -$357M | -$402M | -$413M |
| Shares (wtd avg diluted) | 33.3M | 34.6M | 38.6M | 37.6M | 42.1M | 46.0M | 45.7M | 46.3M | 47.0M | 47.8M |
Every figure is extracted from AtriCure, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.